

Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/J4899B3CE457EN.html>

Date: April 2022

Pages: 96

Price: US\$ 2,000.00 (Single User License)

ID: J4899B3CE457EN

Abstracts

Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration - Drugs In Development, 2022, provides an overview of the Juvenile Macular Degeneration (Ophthalmology) pipeline landscape.

Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt's disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Juvenile Macular Degeneration - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Juvenile Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 7, 1, 14 and 12 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Juvenile Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Juvenile Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Juvenile Macular Degeneration (Stargardt Disease) - Overview

Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Juvenile Macular Degeneration (Stargardt Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Juvenile Macular Degeneration (Stargardt Disease) - Companies Involved in

Therapeutics Development

4P-Pharma SAS

Alkeus Pharmaceuticals Inc

Anylam Pharmaceuticals Inc

Alpine Biotherapeutics Corp

Applied Genetic Technologies Corp

Astellas Pharma Inc

Beam Therapeutics Inc

Belite Bio Inc

Biophytis SA

Brooklyn ImmunoTherapeutics Inc

Cardax Inc

Coave Therapeutics

Copernicus Therapeutics Inc

Curative Biotechnology Inc

Fera Pharmaceuticals LLC

Generation Bio Co

Grupo Ferrer Internacional SA

IVERIC bio Inc

jCyte Inc

Katairo GmbH

Kubota Vision Inc

Lysoclear Inc
Mediphage Bioceuticals Inc
Nanoscope Therapeutics Inc
Oak bay Biosciences Ltd
ProQR Therapeutics NV
Ray Therapeutics Inc
ReVision Therapeutics Inc
Saliogen Therapeutics Inc
Shape Therapeutics Inc
Spark Therapeutics Inc
Splice Bio SL
Stargazer Pharmaceuticals Inc
Juvenile Macular Degeneration (Stargardt Disease) - Drug Profiles
4P-020 - Drug Profile
Product Description
Mechanism Of Action
ALK-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Aptamer to Inhibit CFD for Juvenile Macular Degeneration (Stargardt Disease) - Drug Profile
Product Description
Mechanism Of Action
ASP-7317 - Drug Profile
Product Description
Mechanism Of Action
History of Events
avacincaptad pegol sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
BIO-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CDX-301 - Drug Profile
Product Description
Mechanism Of Action

CTxABCA-4 - Drug Profile

Product Description

Mechanism Of Action

ecothiopate iodide - Drug Profile

Product Description

Mechanism Of Action

History of Events

emixustat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

FAB-111 - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy 1 to Activate ABCA4 for Stargardt Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene therapy for Juvenile Macular Degeneration (Stargardt Disease) - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy To Activate ABCA4 for Stargardt Disease - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate ABCA4 for Stargardt Disease - Drug Profile

Product Description

Mechanism Of Action

GTSG - Drug Profile

Product Description

Mechanism Of Action

Jcell - Drug Profile

Product Description

Mechanism Of Action

History of Events

Lead program in Stargardt disease - Drug Profile

Product Description

Mechanism Of Action

metformin - Drug Profile

Product Description

Mechanism Of Action

History of Events

miniABCA4: STGD1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

QR-1011 - Drug Profile

Product Description

Mechanism Of Action

RAY-001 - Drug Profile

Product Description

Mechanism Of Action

Recombinant Enzyme for Age Related Macular Degeneration and Stargardt Disease -
Drug Profile

Product Description

Mechanism Of Action

History of Events

REV-0100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SHP-261 - Drug Profile

Product Description

Mechanism Of Action

soraprazan - Drug Profile

Product Description

Mechanism Of Action

History of Events

Stargardt - Drug Profile

Product Description

Mechanism Of Action

Stargardt Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Stem Cell Therapy for Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

History of Events

STG-001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TFB for Dry Age-Related Macular Degeneration, Stargardt Macular Dystrophy - Drug Profile

Product Description

Mechanism Of Action

tinlarebant - Drug Profile

Product Description

Mechanism Of Action

History of Events

VMCO-1 - Drug Profile

Product Description

Mechanism Of Action

History of Events

vutrisiran - Drug Profile

Product Description

Mechanism Of Action

History of Events

Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects

Juvenile Macular Degeneration (Stargardt Disease) - Product Development Milestones

Featured News & Press Releases

Apr 12, 2022: Fera Pharmaceuticals announces FDA Orphan Designation of

Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule T...

Phospholine Iodide for the treatment of Stargardt disease

Jan 25, 2022: Nanoscope Therapeutics announces FDA clearance of IND for MCO-010 gene therapy in Stargardt macular degeneration patients

Jan 10, 2022: Nanoscope awarded key U.S. patent protecting its multi-characteristic Opsin Gene Therapy platform for reversing blindness

Aug 25, 2021: Aequus strengthens clinical experience in Stargardt disease with pediatric ophthalmology expertise

Jul 14, 2021: FDA grants Alkeus Pharmaceuticals Breakthrough Therapy designation for ALK-001 (C20-D3-vitamin A) for the treatment of Stargardt Disease

Jun 30, 2021: Belite Bio announces start of LBS-008 phase 3 Stargardt Disease trial

Mar 03, 2021: Nanoscope president to deliver talk on gene therapy for retinal diseases at Association for Ocular Pharmacology and Therapeutics conference

Jan 25, 2021: Nanoscope Therapeutics receives Orphan Drug Designation for gene therapy of blindness

Nov 24, 2020: Kubota Vision announces publication of Emixustat's pharmacodynamic effects in patients with stargardt disease

Oct 28, 2020: reVision Therapeutics announces US FDA Grant of rare pediatric disease and orphan-drug designation for REV-0100 for the treatment of Stargardt disease

Aug 20, 2020: Kubota Vision receives orphan products clinical trials grants to Emixustat for stargardt disease

Jul 20, 2020: Belite Bio announces positive results from phase 1 clinical trials of LBS-008

May 01, 2020: Kubota Vision completes enrollment in the Emixustat phase 3 clinical trial in patients with Stargardt disease

Feb 13, 2020: Acucela provides update on Emixustat phase 3 clinical trial in patients with Stargardt disease

Jan 06, 2020: Acucela announces publication assessing the role of Emixustat Hydrochloride in retinal degeneration treatment

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by 4P-Pharma SAS, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alnylam Pharmaceuticals Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alpine Biotherapeutics Corp, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Applied Genetic Technologies Corp, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Astellas Pharma Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Beam Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Belite Bio Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Biophytis SA, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Brooklyn ImmunoTherapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Cardax Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Coave Therapeutics, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Copernicus Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Curative

Biotechnology Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Fera Pharmaceuticals LLC, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Generation Bio Co, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Grupo Ferrer Internacional SA, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by IVERIC bio Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by jCyte Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Katairo GmbH, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Kubota Vision Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Lysoclear Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Mediphage Bioceuticals Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Nanoscope Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Oak bay Biosciences Ltd, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by ProQR Therapeutics NV, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Ray Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by ReVision Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Saliogen Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Shape Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Spark Therapeutics Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Splice Bio SL, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Stargazer Pharmaceuticals Inc, 2022

Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Juvenile Macular Degeneration (Stargardt Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/J4899B3CE457EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/J4899B3CE457EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

